MedReleaf has launched a new medicinal cannabis brand in Australia in partnership with Canadian firm Aurora Cannabis. 

The CraftPlant brand includes three products for doctors to prescribe – Greendae, Navana and HiVolt – all of which are THC-dominant with high percentages of terpenes. 

MedReleaf CEO Russell Harding

The new range is produced under EU-GMP certified conditions and will be available in 10g containers.

CEO Russell Harding said: “These new products are the result of dedicated hard work by the teams in both Canada and Australia, providing the most unique cannabis cultivars available in the Australian medical market. 

“With CraftPlant, doctors now have 27 MedReleaf products available… providing a wide range of possible solutions for patients unable to obtain relief from their prior medications or treatment, and produced under the strictest guidelines.”

Aurora Cannabis CEO Miguel Martin added: “As we build on our strategic international growth plans, Australia has proven to be a very promising and sustainable cannabis market that we are committed to.”

Aurora holds a 10% stake in MedReleaf Australia.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment